Great question and I look forward to reading answers.
I'm in at a cost basis of $4 with approx 30K shares accumulated over the last 4 years. I'm standing pat through data release as I think the odds of strong data is high. After that, that is where the risk elevates in my opinion because I don't trust FDA, Hedgies, Big P etc.. We should be in the 8-10 range and I'll likely sell a some shares or Jan 2015 calls (by then sb 14 for $2 premiums) to recover my inital investment and let the rest ride forever. Those funds will move to my continuing stake in MAKO which will double in the next 12-18 months.
I think there will be a strong partnership with some upfront money but balance contingent upon approval. If the data is good, I don't see them going it alone because the risk of not getting Afrezza and a competitor getting it is too high. Don't rule out Medtronic Diabetes. Someone will deal. If this happens, I see $12-14
Then it is up to the FDA where I feel anything could happen.
